Research/art/teacher profile of a person
Name and surname:
prof. MUDr. Alexandra Kolenová, PhD.
Document type:
Research/art/teacher profile of a person
The name of the university:
Comenius University Bratislava
The seat of the university:
Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname
Kolenova
I.2 - Name
Alexandra
I.3 - Degrees
Prof.MD.PhD
I.4 - Year of birth
1972
I.5 - Name of the workplace
Department of Pediatric Hematology and Oncology, Medical Faculty Comenius University in Bratislava and National Institute of Children's Diseases
I.6 - Address of the workplace
Limbova 1 Bratislava
I.7 - Position
Professor, Chief of Department
I.8 - E-mail address
kolenova6@uniba.sk
I.9 - Hyperlink to the entry of a person in the Register of university staff
https://www.portalvs.sk/regzam/detail/5485
I.10 - Name of the study field in which a person works at the university
Pediatrics
I.11 - ORCID iD
0000-0003-4300-5533

II. - Higher education and further qualification growth

II.1 - First degree of higher education
II.a - Name of the university or institution
Masaryk University,Medical Faculty
II.b - Year
1997
II.c - Study field and programme
general medicine
II.2 - Second degree of higher education
II.a - Name of the university or institution
Medical Faculty, Comenius University in Bratislava
II.b - Year
2010
II.c - Study field and programme
Pediatrics
II.3 - Third degree of higher education
II.b - Year
2014
II.4 - Associate professor
II.a - Name of the university or institution
Medical Faculty, Comenius University in Bratislava
II.b - Year
2014
II.c - Study field and programme
Pediatrics
II.5 - Professor
II.a - Name of the university or institution
Medical Faculty, Comenius University in Bratislava
II.b - Year
2022
II.c - Study field and programme
Pediatrics
II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position III.b - Institution III.c - Duration
University lecturer or University teacher, Head of the clinic Medical Faculty, Comenius University in Bratislava 2009_ till now
pediatrician, Head of the clinic National Institute of Children's Diseases 2001- till now
physician Hospital in Dolny Kubin 1997-2001

IV. - Development of pedagogical, professional, language, digital and other skills

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes
V.1.a - Name of the profile course V.1.b - Study programme V.1.c - Degree V.1.d - Field of study
Pediatrics, Pediatric Oncology General medicine II. General Medicine
Pediatrics Pediatrics III. General Medicine
V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year
V.2.a - Name of the study programme V.2.b - Degree V.2.c - Field of study
Pediatrics III. General Medicine
V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.4 - Overview of supervised final theses
V.4.1 - Number of currently supervised theses
V.4.b - Diploma (second degree)
5
V.4.c - Dissertation (third degree)
3
V.4.2 - Number of defended theses
V.4.b - Diploma (second degree)
more than 20
V.4.c - Dissertation (third degree)
2
V.5 - Overview of other courses taught in the current academic year according to study programmes

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations
VI.1.1 - Number of the research/artistic/other outputs
VI.1.a - Overall
425
VI.1.b - Over the last six years
181
VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases
VI.1.a - Overall
127
VI.1.b - Over the last six years
48
VI.1.3 - Number of citations corresponding to the research/artistic/other outputs
VI.1.a - Overall
944
VI.1.b - Over the last six years
670
VI.1.4 - Number of citations registered in the Web of Science or Scopus databases
VI.1.a - Overall
944
VI.1.b - Over the last six years
670
VI.1.5 - Number of invited lectures at the international, national level
VI.1.a - Overall
15
VI.1.b - Over the last six years
7
VI.2 - The most significant research/artistic/other outputs
1

Hrušák, Ondřej, De Haas, Valerie, Stančíková, Jitka, Kolenová, Alexandra et al. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood: the journal of hematology. – Washington (USA) : American Society of Hematology.Roč. 132, č. 3 (2018), s. 264-276 IF: 16.601, Q1)

2

Donadieu, Jean, Larabi, Islam Amine, Tardieu, Mathilde, Visser, Johannes, Hutter, Caroline, Kolenová, Alexandra et al: Vemurafenib for refractory multisystem langerhans cell histiocytosis in children: An International Observational Study. Journal of clinical oncology Roč. 37, č. 31 (2019), s. 2857-2865 IF: 32,956, Q1)

Schwentner, Raphaela, Kolenová, Alexandra et al.: Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis. Pediatric Research, Roč. 85, č. 6 (2019), s. 856-864 (IF: 2,747, Q1)

3

Alford, Kate A.,Reinhardt, Katarina, Garnett, Catherine, Norton, Alice , Bohmer, Katarina, Kolenová, Alexandra, Vyas, Paresh et al.: Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood Roč. 118, č. 8 (2011), s. 2222-2238, (IF: 9,898, Q1)

4

Meyer, Claus, Hofmann, J., Burmeister, T.Gröger, D. Kolenová, Alexandra (Autor) et al: The MLL recombinome of acute leukemias in 2013. Leukemia,Roč. 27, č. 11 (2013), s. 2165-2176 (IF: 9,379, Q1)

5

Kolenová, Alexandra. Kaiserová, Emília, Makohusová, Miroslava, Šubová, Hunger, Stephen Patrick Starý, Jan et al: Improved outcome for children and adolescent with acute lymphoblastic leukemia in the first decade of the 21st century: a report from the Slovak Republic. Neoplasma,Roč. 62, č. 5 (2015), s. 812-820 (IF: 1,961, Q3)

VI.3 - The most significant research/artistic/other outputs over the last six years
1

Campbell, Myriam, Kiss, Csongor, Zimmermann, Martin, Riccheri, Cecilia, Kolenová, Alexandra et al. : Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial. Journal of clinical oncology, Roč. 41, č. 19 (2023), s. 3499-3511 (IF: 42.1, Q1)

2

R, Loeffen JLC, Pastorczak A, Takagi M, Kolenova A, .Elitzur S, Shiloh et al. ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies Blood. 2024 Sep 12;144(11):1193-1205. doi: 10.1182/blood.2024024283. (IF 21,Q1)

3

Donadieu, Jean, Larabi, Islam Amine, Tardieu, Mathilde, Visser, Johannes, Hutter, Caroline, Kolenová, Alexandra et al: Vemurafenib for refractory multisystem langerhans cell histiocytosis in children: An International Observational Study. Journal of clinical oncology Roč. 37, č. 31 (2019), s. 2857-2865 IF: 32,956, Q1)

4

Hrušák, Ondřej ,Kalina, Tomáš, Wolf, Joshua, Balduzzi, Adriana, Provenzi, Massimo, Kolenová, Alexandra et al. Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. European Journal of Cancer č. 132 (2020), s. 11-16 (IF: 9,162, Q1)

5

Kalinová, Markéta, Mrhalová, Marcela, Kabíčková, Edita, Svatoň, Michael, Skotnicová, Aneta Kolenová, Alexandra et al: Molecular screening in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: anaplastic lymphoma kinase analysis, next-generation sequencing fusion gene detection, and T-Cell receptor immunoprofiling. Modern pathology Roč. 37, č. 3 (2024), ( IF: 7.1 Q1)

VI.4 - The most significant citations corresponding to the research/artistic/other outputs
1

Campbell, Myriam, Kiss, Csongor, Zimmermann, Martin, Riccheri, Cecilia, Kolenová, Alexandra et al. : Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial. Journal of clinical oncology, Roč. 41, č. 19 (2023), s. 3499-3511 (IF: 42.1, Q1)

​

The most important citations:

  1. Rujkijyanont, P., & Inaba, H. (2024). Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in low- and middle-income countries. Leukemia, 38(8), 1649–1662. Táto práca odkazuje na výsledky štúdie ALL IC-BFM 2009 pri diskusii o stratégiách liečby akútnej lymfoblastovej leukémie (ALL) v krajinách s nízkym a stredným príjmom.​www.elsevier.com+3SCIRP+3PMC+3
  2. Chen, J., et al. (2024). Measurable residual disease (MRD)-testing in haematological and solid cancers. Leukemia, 38(6), 1202–1212. Autori citujú štúdiu ALL IC-BFM 2009 pri zdôraznení významu testovania minimálnej reziduálnej choroby (MRD) v hematologických malignitách.​ResearchGate+3www.elsevier.com+3PMC+3
  3. Leung, K. T., et al. (2024). Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China. Leukemia, 38(2), 250–257. Štúdia využíva údaje z ALL IC-BFM 2009 na analýzu prognostického významu CD9 v detskej ALL.​
  4. Baratto, L., et al. (2024). Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [18F]FDG PET/MRI: A Pilot Study. Journal of Nuclear Medicine, 65(6), 864–871. Táto pilotná štúdia odkazuje na protokol ALL IC-BFM 2009 pri hodnotení vplyvu vysokodávkovaného metotrexátu na mozog u detských a mladých dospelých pacientov.​ResearchGate+3SCIRP+3I-BFM+3
  5. Rheingold, S. R., et al. (2024). Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia, 38(11), 2382–2394. Táto štúdia analyzuje faktory ovplyvňujúce prežitie po prvom relapse ALL a odkazuje na výsledky ALL IC-BFM 2009.

2

Meyer, Claus, Hofmann, J., Burmeister, T.Gröger, D. Kolenová, Alexandra (Autor) et al: The MLL recombinome of acute leukemias in 2013. Leukemia,Roč. 27, č. 11 (2013), s. 2165-2176 (IF: 9,379, Q1)

Marschalek, R. (2016). Systematic Classification of Mixed-Lineage Leukemia Fusion Partners Predicts Additional Cancer Pathways. Annals of Laboratory Medicine, 36(2), 85–100.

Táto práca využíva údaje z článku z roku 2013 na systematickú klasifikáciu fúznych partnerov génu MLL a predpovedá ďalšie onkogénne dráhy.

Garrido Castro, P., et al. (2018). The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis. Leukemia, 32(2), 323–331.

Štúdia odkazuje na článok z roku 2013 pri skúmaní účinnosti inhibítora HDAC panobinostat proti akútnej lymfoblastovej leukémii s MLL-rearanžmánmi.

De Braekeleer, E., et al. (2010). Complex and cryptic chromosomal rearrangements involving the MLL gene in acute leukemia: a study of 7 patients and review of the literature. Blood Cells, Molecules, and Diseases, 44(4), 268–274.

Táto práca cituje článok z roku 2013 pri analýze komplexných a kryptických chromozomálnych prestavieb zahŕňajúcich gén MLL u pacientov s akútnou leukémiou.

Lazar, T., et al. (2016). Intrinsic protein disorder in histone lysine methylation. Biology Direct, 11, 30.

Autori odkazujú na článok z roku 2013 pri diskusii o vnútornom neporiadku proteínov v metylácii lyzínu histónov.

Moschiano, E., et al. (2016). Congenital B-lymphoblastic leukemia with a cryptic MLL rearrangement and post-treatment evolution to mixed phenotype acute leukemia. Leukemia Research Reports, 6, 29–32.

Štúdia využíva poznatky z článku z roku 2013 pri skúmaní kongenitálnej B-lymfoblastovej leukémie s kryptickou MLL prestavbou

3

Schwentner, Raphaela, Kolenová, Alexandra et al.: Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis. Pediatric Research, Roč. 85, č. 6 (2019), s. 856-864 (IF: 2,747, Q1)

Cui, L., et al. (2020). Circulating cell-free BRAF V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis. Haematologica, 105(9), e444–e447.

Táto štúdia odkazuje na článok z roku 2019 pri skúmaní prognostického významu cirkulujúcej bezbunkovej DNA BRAF V600E počas chemoterapie u detských pacientov s Langerhansovou bunkovou histiocytózou.

Eckstein, O. S., et al. (2019). Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood, 133(15), 1691–1694.

Autori citujú štúdiu z roku 2019 pri hodnotení klinických odpovedí a perzistencie BRAF V600E pozitívnych krvných buniek u detí s LCH liečených inhibítormi MAPK dráhy.

Zhang, R., et al. (2023). Advances in our understanding of genetic markers and targeted therapy in Langerhans cell histiocytosis. Expert Review of Hematology, 16(4), 289–300.

Táto prehľadová práca odkazuje na článok z roku 2019 pri diskusii o genetických markeroch a cielenej terapii v Langerhansovej bunkovej histiocytóze.

Histiocyte Society (2020). LCH Articles.

Oficiálna stránka Histiocyte Society uvádza článok z roku 2019 ako významný príspevok k literatúre o Langerhansovej bunkovej histiocytóze.

4

Hrušák, Ondřej, De Haas, Valerie, Stančíková, Jitka, Kolenová, Alexandra et al. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood: the journal of hematology. – Washington (USA) : American Society of Hematology.Roč. 132, č. 3 (2018), s. 264-276 IF: 16.601, Q1)

Lee, H. G., et al. (2019). Biphenotypic acute leukemia or acute leukemia of ambiguous lineage in childhood: clinical characteristics and outcome. Blood Research, 54(1), 63–73. Táto štúdia analyzuje klinické charakteristiky a výsledky detských pacientov s biphenotypickou akútnou leukémiou, pričom odkazuje na prácu Hrušáka et al. pri diskusii o liečebných stratégiách.

Gao, H. Q., et al. (2021). Clinical features and prognosis of children with acute leukemias of ambiguous lineage under different diagnostic criteria. Zhongguo Dang Dai Er Ke Za Zhi, 23(8), 835–840. Štúdia skúma prognózu detí s akútnymi leukémiami nejednoznačnej línie podľa rôznych diagnostických kritérií a cituje výsledky Hrušáka et al.

de Haas, V., et al. (2019). Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline. Journal of Clinical Oncology, 37(3), 239–253. Táto smernica odkazuje na štúdiu Hrušáka et al. pri stanovovaní odporúčaní pre počiatočnú diagnostiku akútnej leukémie.

5

Alford, Kate A.,Reinhardt, Katarina, Garnett, Catherine, Norton, Alice , Bohmer, Katarina, Kolenová, Alexandra, Vyas, Paresh et al.: Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood Roč. 118, č. 8 (2011), s. 2222-2238, (IF: 9,898, Q1)

​

  1. Kanezaki, R., et al. (2010). Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood, 116(22), 4631–4638. Táto štúdia skúma koreláciu medzi typmi mutácií GATA1 a progresiou z transientnej myeloproliferatívnej poruchy (TMD) k myeloidnej leukémii u detí s Downovým syndrómom, pričom odkazuje na prácu Alforda a kol. pri analýze mutácií GATA1.
  2. Li, J., & Kalev-Zylinska, M. L. (2022). Advances in molecular characterization of myeloid proliferations associated with Down syndrome. Frontiers in Genetics, 13, 891214. Táto prehľadová práca diskutuje pokroky v molekulárnej charakterizácii myeloidných proliferácií spojených s Downovým syndrómom a cituje štúdiu Alforda a kol. pri analýze mutácií GATA1 v TMD a myeloidnej leukémii.
  3. Garnett, C., Cruz Hernandez, D., & Vyas, P. (2020). GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome. IUBMB Life, 72(1), 119–130. Autori skúmajú úlohu mutácií GATA1 a spolupracujúcich genetických zmien v patogenéze myeloidnej leukémie u detí s Downovým syndrómom, pričom odkazujú na výsledky Alforda a kol. pri analýze mutácií GATA1.
  4. Watanabe, K. (2019). Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome. Pediatrics International, 61(3), 222–229. Táto prehľadová práca sumarizuje aktuálne poznatky o transientnej abnormálnej myelopoéze u detí s Downovým syndrómom a cituje prácu Alforda a kol. pri diskusii o mutáciách GATA1.
  5. Queiroz, L. B., et al. (2013). Analysis of GATA1 mutations and leukemogenesis in newborns with Down syndrome. Genetics and Molecular Research, 12(4), 4630–4638. Štúdia analyzuje mutácie GATA1 a ich úlohu v leukemogenéze u novorodencov s Downovým syndrómom, pričom odkazuje na prácu Alforda a kol. pri hodnotení detekcie mutácií GATA1.

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years
1

Principal Investigator for the Slovak Republic, AIEOP-BFM ALL 2017 International Collaborative Treatment Protocol for Children and Adolescents with Acute Lymphoblastic Leukemia, Randomized Phase III Study, EudraCT Number AIEOP-BFM ALL 2017: 2016-001935-12

2

Principal Investigator for the Slovak Republic, Interfant-21: International Treatment Protocol for Infants under One Year of Age with KMT2A Rearrangement and Acute Lymphoblastic Leukemia

3

Principal Investigator APVV-23-0657: Integration of Methylation Array and Targeted Sequencing for Personalized Care of Children with Brain Tumors

4

For the Slovak Republic, Protocol A5481092 PHASE 1/2 STUDY to Evaluate Palbociclib in Pediatric Patients with Relapsed or Refractory Solid Tumors

5

Principal Investigator for the Slovak Republic, Protocol B1931036, PHASE 2, PROSPECTIVE, RANDOMIZED STUDY in Children with High-Risk Relapse of Precursor B-Cell Acute Lymphoblastic Leukemia

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VII.a - Activity, position VII.b - Name of the institution, board VII.c - Duration
Member of the Scientific Council Medical Faculty, Comenius University in Bratislava 2023 - till present
Member of the Scientific Council Comenius University 2023- till present
Member of the Accreditation Committee Medical Faculty, Comenius University in Bratislava 2024 - till present
Guarantor in the Field of Pediatric Hematology and Oncology Medical Faculty, Comenius University in Bratislava 2015- till present
Member of the Guarantor Group in the Field of Pediatrics Medical Faculty, Comenius University in Bratislava 2019 - till present

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

VIII.a - Name of the institution VIII.b - Address of the institution VIII.c - Duration (indicate the duration of stay) VIII.d - Mobility scheme, employment contract, other (describe)
Childrenś Hospital of Colorado Aurora, Denver, USA 2013/2014 Slovak - America Foundation, Reaserch Scholar
Children Hospital of Philadelphia, University of Pennsylvania Philadelphia, USA 6 months, 2024/2025 Fulbright Scholarship
St. Ana Kinderspital Vienna, Austria 6 months in 2005 Gigax scholarship
Salzburg seminar Salzgburg, Austria 2001/1 week Salzgburg seminar Open Society
Princess Maxima Centrum Utrecht, Holland 2023 - long term cooperation Memorandum of Cooperation in Education, Exchange Programs
Motol Prague Prague, Czech Republic 2012 Exchange Research Stay in the Field of Minimal Residual Disease

IX. - Other relevant facts

IX.a - If relevant, other activities related to higher education or research/artistic/other activities are mentioned

Chief Expert of the Ministry of Health of the Slovak Republic for Pediatric Oncology

Guarantor of the Specialization in Pediatric Hematology and Oncology

President of the Pediatric Oncology and Hematology Section of the Slovak Medical Society’s Pediatric Division

Chairwoman of the Board of Trustees of the non-profit organization Children with Cancer

Awards and Honors:

  • State Decoration by the President of the Slovak Republic in 2023: Pribina Cross, 1st Class for contributions in the field of healthcare
  • Fulbright Scholarship in 2024/2025: Research stay at CHOP and UPENN, Philadelphia, USA
  • Listed among the Top 75 Doctors in Slovakia by Forbes magazine in 2024 and 2025
  • Top Innovations in 2017 and 2018
  • Slovak American Foundation Research Fellowship in 2013/2014
  • Gigax Scholarship in 2005: Completed international internship at St. Anna Children’s Hospital in Austria